StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research note released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
NASDAQ:GLMD remained flat at $0.39 during mid-day trading on Thursday. The company’s stock had a trading volume of 22,429 shares, compared to its average volume of 261,749. The business has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.38. Galmed Pharmaceuticals has a one year low of $0.26 and a one year high of $7.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last released its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Recommended Stories
- Five stocks we like better than Galmed Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 4/29 – 5/3
- Investing in large cap stocks: Diving into big caps
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Ride Out The Recession With These Dividend Kings
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.